Shots: Vifor and Janssen collaborated to jointly commercialize Invokana (canagliflozin) to treat DKD and to reduce the risk of hospitalization for heart failure in patients with T2D and DKD in the US The Vifor Pharma will utilize it salesforce to promote Invokana to nephrologists which further supports its goal of becoming a leader in nephrology […]Read More
Shots: The approval is based on P-III CREDENCE study evaluating the renal outcomes of Invokana + SoC vs PBO in 4,401 patients with T2D with stage II/III DKD and macroalbuminuria who were receiving SoC including ACE inhibitors & ARB The P-III CREDENCE study resulted in 30% reduction in 1EPs i.e, end-stage kidney disease (ESKD), doubling […]Read More
Shots: The P-III CREDENCE study results involves assessing of Invokana (100 mg, qd) vs PBO in patients 4,401 patients in ratio (1:1) with T2D and stage II &III CKD prior treated with ACE inhibitors or angiotensin II receptor blockers The P-III CREDENCE study results: 20% reduction in risk of CV death, heart stroke & death […]Read More
Shots: The approval is based on the results of CANVAS (CANagliflozin cardioVascular Assessment Study) Program assessing Invokana vs PBO + SoC in 10,000 adults having or at risk CV disease with T2D & recommendations from ADA & AACE for Invokana + SGLT2 inhibitor to reduce CV events CANVAS study results: overall reduction in risk of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
